Xstelos Holdings Quick Ratio (XTLS) starting from the third quarter 2013 to third quarter 2012, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Xstelos Holdings, Inc.  (XTLS)

Xstelos Holdings's Quick Ratio

XTLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2013, Quick Ratio deteriorated to 1.09 below Xstelos Holdings's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Quick Ratio than Xstelos Holdings in third quarter 2013. While Quick Ratio total ranking has improved so far during the Q3 2013 to 1321, from total ranking in the second quarter 2013 at 1557.

Explain Quick Ratio?
How much Cash & cash equivalents XTLS´s has?
What are XTLS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XTLS Quick Ratio (Sep 30 2013)
Q3		 (Jun 30 2013)
Q2		 (Mar 31 2013)
Q1		 (Dec 31 2012)
Q4		 (Sep 30 2012)
Q3
Y / Y Current Liabilities Change -15.48 % -2.4 % 4.58 % - -
Y / Y Cash & cash equivalent Change -42.18 % -31.59 % 59.32 % - -
Quick Ratio MRQ 1.09 1.13 1.2 1.09 1.59
XTLS's Total Ranking # 1321 # 1557 # 1555 # 1345 # 1017
Seq. Current Liabilities Change -12.13 % -0.68 % -5.55 % 2.54 % 1.47 %
Seq. Cash & cash equivalent Change -15.67 % -6.52 % 4.55 % -29.85 % -0.22 %



Quick Ratio third quarter 2013 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 47
Healthcare Sector # 306
Overall Market # 1321


Quick Ratio Statistics
High Average Low
1.62 1.22 0.79
(Jun 30 2012)   (Mar 31 2012)




Financial Statements
Xstelos Holdings's Current Liabilities $ 14 Millions Visit XTLS's Balance sheet
Xstelos Holdings's Cash & cash equivalent $ 15 Millions Visit XTLS's Balance sheet
Source of XTLS's Sales Visit XTLS's Sales by Geography


Cumulative Xstelos Holdings's Quick Ratio

XTLS's Quick Ratio for the trailling 12 Months

XTLS Quick Ratio

 (Sep 30 2013)
12 Months		 (Jun 30 2013)
12 Months		 (Mar 31 2013)
12 Months		 (Dec 31 2012)
12 Months		 (Sep 30 2012)
12 Months
Y / Y Current Liabilities TTM Growth 30.55 % 106.94 % 329.73 % - -
Y / Y Cash & cash equivalent TTM Growth 9.59 % 113.36 % 646.64 % - -
Quick Ratio TTM 1.13 1.25 1.37 1.28 1.35
Total Ranking TTM # 369 # 1249 # 1539 # 1543 # 1383
Seq. Current Liabilities TTM Growth -3.91 % -0.59 % 1.08 % 35.22 % 52.31 %
Seq. Cash & cash equivalent TTM Growth -13.52 % -9.21 % 8.63 % 28.49 % 68.37 %

Quick ratio ranking by company, industry and sector >> Back to XTLS Financial Strength Comparisons >> Go to Compare XTLS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in XTLS's Current Liabilities to $13.72 millions, cumulative Quick Ratio to 1.13 below the XTLS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Quick Ratio than Xstelos Holdings. While Quick Ratio overall ranking has improved so far to 369, from total ranking during the twelve months ending second quarter 2013 at 1249.

Explain Quick Ratio?
How much Cash & cash equivalents XTLS´s has?
What are XTLS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 62
Within the Market # 369


trailing twelve months Quick Ratio Statistics
High Average Low
1.37 1.21 0.99
(Mar 31 2013)   (Sep 30 2012)




Companies with similar Quick Ratio in the quarter ending Sep 30 2013, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2013 MRQ Cash & cash equivalentSep 30 2013 MRQ Current Liabilities
Telik Inc  2.55 $ 3.197  Millions$ 1.255  Millions
Gentium S.p.a.  2.37 $ 16.154  Millions$ 6.808  Millions
Champions Oncology Inc   2.32 $ 7.572  Millions$ 3.269  Millions
Adma Biologics Inc   2.14 $ 5.380  Millions$ 2.517  Millions
Fate Therapeutics Inc   2.01 $ 19.082  Millions$ 9.491  Millions
Cadence Pharmaceuticals Inc  1.97 $ 54.854  Millions$ 27.789  Millions
Windtree Therapeutics Inc  1.87 $ 21.177  Millions$ 11.310  Millions
Cellular Biomedicine Group Inc   1.84 $ 3.465  Millions$ 1.886  Millions
Qiagen N v   1.82 $ 484.488  Millions$ 266.869  Millions
Ladrx Corporation  1.73 $ 23.036  Millions$ 13.325  Millions
Halozyme Therapeutics Inc   1.65 $ 65.311  Millions$ 39.624  Millions
Dendreon Corp  1.50 $ 166.641  Millions$ 110.755  Millions
Vericel Corporation  1.49 $ 10.816  Millions$ 7.252  Millions
Lineage Cell Therapeutics Inc   1.48 $ 6.717  Millions$ 4.551  Millions
Xstelos Holdings, Inc.  1.09 $ 14.928  Millions$ 13.721  Millions
Polarityte Inc   0.76 $ 13.385  Millions$ 17.596  Millions
Zeo Scientifix Inc   0.75 $ 0.016  Millions$ 0.021  Millions
Titan Pharmaceuticals Inc   0.63 $ 8.998  Millions$ 14.192  Millions
Premier Biomedical Inc  0.63 $ 0.074  Millions$ 0.117  Millions
Cel sci Corporation  0.60 $ 2.113  Millions$ 3.545  Millions
Pharmacyte Biotech Inc   0.53 $ 0.397  Millions$ 0.754  Millions
Bohai Pharmaceuticals Group, Inc.  0.53 $ 27.091  Millions$ 51.512  Millions
Gene Biotherapeutics Inc   0.50 $ 0.585  Millions$ 1.167  Millions
Biogen Inc   0.44 $ 668.693  Millions$ 1,518.711  Millions
Gilead Sciences Inc   0.43 $ 2,090.494  Millions$ 4,895.124  Millions
Xtant Medical Holdings Inc   0.39 $ 3.438  Millions$ 8.852  Millions
Enzo Biochem Inc  0.36 $ 7.426  Millions$ 20.596  Millions
Aerie Pharmaceuticals Inc   0.26 $ 4.619  Millions$ 18.112  Millions
Eloxx Pharmaceuticals Inc   0.22 $ 0.789  Millions$ 3.598  Millions

Date modified: 2026-09-18T13:11:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.